000144822 001__ 144822
000144822 005__ 20240229112638.0
000144822 0247_ $$2doi$$a10.1007/s00292-019-00657-y
000144822 0247_ $$2pmid$$apmid:31511974
000144822 0247_ $$2ISSN$$a0172-8113
000144822 0247_ $$2ISSN$$a1432-1963
000144822 0247_ $$2altmetric$$aaltmetric:66553096
000144822 037__ $$aDKFZ-2019-02247
000144822 041__ $$ager
000144822 082__ $$a610
000144822 1001_ $$aDutzmann, C. M.$$b0
000144822 245__ $$a[Update on Li-Fraumeni syndrome].
000144822 260__ $$aNew York$$bSpringer$$c2019
000144822 3367_ $$2DRIVER$$aarticle
000144822 3367_ $$2DataCite$$aOutput Types/Journal article
000144822 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1577095625_24059$$xReview Article
000144822 3367_ $$2BibTeX$$aARTICLE
000144822 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000144822 3367_ $$00$$2EndNote$$aJournal Article
000144822 520__ $$aThe Li-Fraumeni syndrome (LFS, online Mendelian inheritance in man, OMIM #151623) is considered to be one of the currently known most aggressive cancer predisposition syndromes. The heterogeneous spectrum of tumors is dominated by bone and soft tissue sarcomas, various brain tumors, premenopausal breast cancer and adrenocortical carcinoma (ACC). Even in childhood the cancer risk is very strongly increased and it is not uncommon for people with LFS to develop synchronous and metachronous tumors. Typical histopathological findings and molecular genetic signatures can help towards the diagnosis. Inheritance is autosomal dominant and the penetrance appears to be more variable than previously thought. The prevalence of LFS is approximately 1:5000 with a high interregional variance. The LFS is caused by germline mutations in the TP53 gene coding for the protein p53, an essential cellular transcription factor that initiates antitumor responses to cellular stress, such as DNA damage. In people with LFS, due to the loss of functional p53, the protective mechanism of the cells is weakened resulting in a significantly increased cancer risk. In order to improve the survival of people with LFS, structured tumor early recognition and surveillance strategies are recommended; however, national and international longitudinal observational studies are needed to evaluate the cost-effort-benefit balance. For this reason, the authors have established the LFS cancer predisposition registry in which all patients with LFS and other syndromes predisposing to cancer can be registered. Detailed information can be found at www.cancer-predisposition.org .
000144822 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000144822 588__ $$aDataset connected to CrossRef, PubMed,
000144822 7001_ $$aVogel, J.$$b1
000144822 7001_ $$aKratz, C. P.$$b2
000144822 7001_ $$0P:(DE-HGF)0$$aPajtler, K. W.$$b3
000144822 7001_ $$0P:(DE-HGF)0$$aPfister, S. M.$$b4
000144822 7001_ $$aDörgeloh, B. B.$$b5
000144822 773__ $$0PERI:(DE-600)1462980-x$$a10.1007/s00292-019-00657-y$$n6$$p592-599$$tDer Pathologe$$v40$$x1432-1963$$y2019
000144822 909CO $$ooai:inrepo02.dkfz.de:144822$$pVDB
000144822 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000144822 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000144822 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000144822 9141_ $$y2019
000144822 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000144822 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bPATHOLOGE : 2017
000144822 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000144822 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000144822 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000144822 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000144822 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000144822 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000144822 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000144822 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000144822 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000144822 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lPädiatrische Neuroonkologie$$x0
000144822 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x1
000144822 980__ $$ajournal
000144822 980__ $$aVDB
000144822 980__ $$aI:(DE-He78)B062-20160331
000144822 980__ $$aI:(DE-He78)L101-20160331
000144822 980__ $$aUNRESTRICTED